Active Ingredient History
Atropine inhibits the muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic nerves, and on smooth muscles which respond to endogenous acetylcholine but are not so innervated. As with other antimuscarinic agents, the major action of atropine is a competitive or surmountable antagonism which can be overcome by increasing the concentration of acetylcholine at receptor sites of the effector organ (e.g., by using anticholinesterase agents which inhibit the enzymatic destruction of acetylcholine). The receptors antagonized by atropine are the peripheral structures that are stimulated or inhibited by muscarine (i.e., exocrine glands and smooth and cardiac muscle). Responses to postganglionic cholinergic nerve stimulation also may be inhibited by atropine but this occurs less readily than with responses to injected (exogenous) choline esters. Atropine is relatively selective for muscarinic receptors. Its potency at nicotinic receptors is much lower, and actions at non-muscarinic receptors are generally undetectable clinically. Atropine does not distinguish among the M1, M2, and M3 subgroups of muscarinic receptors. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Heart Arrest (approved 2001)
Mushroom Poisoning (approved 2001)
Organophosphate Poisoning (approved 2001)
Sialorrhea (approved 2001)
Amblyopia (Phase 4)
Amyotrophic Lateral Sclerosis (Phase 2)
Anesthesia (Phase 4)
Anesthesia, General (Phase 3)
Anesthesia, Spinal (Phase 4)
Anisometropia (Phase 3)
Arrhythmias, Cardiac (Phase 4)
Arthroplasty, Replacement, Hip (Phase 3)
Arthroplasty, Replacement, Knee (Phase 3)
Autonomic Nervous System Diseases (Phase 1)
Bariatric Surgery (Early Phase 1)
Blood Coagulation (Phase 3)
Blood Pressure (Phase 4)
Bradycardia (Phase 4)
Breast Neoplasms (Phase 2)
Cataract (Phase 4)
Cerebral Palsy (Early Phase 1)
Cesarean Section (Phase 4)
Chest Pain (Phase 3)
Child (Phase 3)
Cognitive Dysfunction (Phase 4)
Conscious Sedation (Phase 4)
Delayed Emergence from Anesthesia (Phase 4)
Dental Care for Disabled (Phase 4)
Dexmedetomidine (Phase 4)
Digestive System Physiological Phenomena (Phase 1)
Dopamine beta-Hydroxylase (Phase 1)
Drugs, Investigational (Phase 1)
Esophageal Achalasia (Phase 4)
Eye Diseases (Phase 4)
Fibrinolytic Agents (Phase 3)
Fractures, Bone (Phase 4)
Gallstones (Phase 4)
Gastrectomy (Early Phase 1)
Gastric Bypass (Early Phase 1)
Gastrointestinal Hormones (Phase 1)
Gastrointestinal Motility (Phase 1)
General Surgery (Phase 4)
Glucagon-Like Peptide 1 (Phase 1)
Gynecology (Phase 4)
Healthy Volunteers (Phase 1)
Heart Arrest (Phase 2)
Hypoglycemia (Early Phase 1)
Hypospadias (Phase 2/Phase 3)
Hypotension (Phase 4)
Hypotension, Orthostatic (Phase 1)
Hypoxia (Phase 4)
Infant, Newborn (Phase 4)
Infant, Premature (Phase 4)
Insecticides (Phase 1)
Insulin Resistance (Early Phase 1)
Intubation (Phase 4)
Intubation, Intratracheal (Phase 4)
Laparoscopy (Phase 4)
Lung Diseases (Phase 4)
Lymphoma (Phase 3)
Muscle Relaxants, Central (Phase 4)
Mydriasis (Phase 4)
Myopia (Phase 4)
Myopia, Degenerative (Phase 3)
Nausea (Phase 4)
Neuromuscular Blockade (Phase 4)
Ocular Physiological Phenomena (Phase 2)
Organophosphate Poisoning (Phase 2/Phase 3)
Orthostatic Intolerance (Phase 1)
Pain (Phase 4)
Pediatrics (Phase 2/Phase 3)
Perfusion (Phase 2/Phase 3)
Pharmacokinetics (Phase 1)
Pneumonia, Ventilator-Associated (Phase 2)
Poisoning (Phase 4)
Post-Dural Puncture Headache (Phase 4)
Postoperative Complications (Early Phase 1)
Postoperative Nausea and Vomiting (Phase 4)
Prediabetic State (Phase 1)
Pregnancy (Phase 4)
Premedication (Phase 2/Phase 3)
Refractive Errors (Phase 4)
Regional Blood Flow (Phase 2)
Respiratory Distress Syndrome, Newborn (Phase 4)
Retinal Diseases (Phase 4)
Rhinitis, Allergic, Seasonal (Phase 3)
Scopolamine (Phase 2)
Sialorrhea (Early Phase 1)
Strabismus (Phase 3)
Urinary Tract Infections (Phase 4)
Vasoconstriction (Early Phase 1)
Vasodilation (Early Phase 1)
Vomiting (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
